NEUROPEPTIDE AND TRANSMITTER ACTION IN SECRETORY CELLS

  • Schonbrunn, Agnes, (PI)

Project: Research projectResearch Project, High Priority, Short Term Project Award

Description

The proposed studies are aimed at understanding the molecular events
involved in the action of inhibitory regulators of cell function from their
initial interaction with target cell receptors to the final biological
response of reduced secretion. The major objective of the present research
plan is to investigate the mechanism by which the neuropeptide somatostatin
elicits its effects in different target cells. The studies proposed will
focus on the actions of somatostatin in two clonal cell lines: and
endocrine cell line derived from th anterior pituitary and a
neuroblastoma-derived cell strain. These cells have retained many of the
differentiated functions of the tissue of origin and possess several unique
properties which readily permit studies that would be difficult or
impossible to interpret in other systems. Furthermore, preliminary studies
indicate that the somatostatin receptor in these two cell lines are
different. The following aspects of somatostatin action will be examined: 1. Mechanisms by which somatostatin regulates intracellular free Ca2+
concentrations and the importance of the induced changes in cytosolic free
Ca2+ in mediating somatostatin inhibition of secretion. 2. Regulation of the binding and transduction properties of the
somatostatin receptor. 3. MEchanisms by which somatostatin action is terminated. 4. Comparison of the binding properties, ligand processing capabilities and
structures of somatostatin receptors in endocrine and neural target cells. A minor objective of this research plan is to examine the regulation of
pituitary function by the neurotransmitter adenosine. Therefore the
effects of adenosine receptor agonists and antagonists on pituitary hormone
secretion will be determined in primary cultures. In addition, the
intracellular mediators involved in adenosine action will be examined in
the clonal pituitary cell line.
StatusFinished
Effective start/end date4/1/836/30/15

Funding

  • National Institutes of Health: $337,854.00
  • National Institutes of Health: $307,970.00
  • National Institutes of Health
  • National Institutes of Health: $316,325.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $334,275.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $331,097.00
  • National Institutes of Health: $327,786.00
  • National Institutes of Health: $347,944.00
  • National Institutes of Health: $324,722.00
  • National Institutes of Health: $114,000.00
  • National Institutes of Health
  • National Institutes of Health: $289,100.00
  • National Institutes of Health
  • National Institutes of Health: $331,097.00

Fingerprint

Somatostatin Receptors
Somatostatin
Neuropeptides
Cell Line
Adenosine
Purinergic P1 Receptor Agonists
GTP-Binding Proteins
Purinergic P1 Receptor Antagonists
Neurotransmitter Agents
Complementary DNA
Phosphorylation
Ligands
Hormones

Keywords

  • Medicine(all)